<DOC>
	<DOCNO>NCT00982774</DOCNO>
	<brief_summary>A phase 1 , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , immunogenicity three injection 10 µg LEISH-F2 + 25 µg MPL-SE give 14-day interval adjunct standard chemotherapy sodium stibogluconate ( 20 mg/kg/day 40 day ) patient PKDL .</brief_summary>
	<brief_title>Safety Immunogenicity LEISH-F2 + MPL-SE Vaccine With SSG Patients With PKDL</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female = 7 year &lt; 40 year age . Must skin rash &gt; 6 month duration compatible diagnosis PKDL follow history successful treatment VL , histopathology consistent PKDL ( Section 6.1 ) . Female patient child bear age must negative serum pregnancy test screening , negative urine pregnancy test within 24 hour study injection , must breastfeed , require use adequate contraception Day 59 study . These precaution necessary due unknown effect LEISHF2 + MPLSE might fetus newborn infant . The following laboratory blood test must value within normal range screen ( Appendix 3 ) : sodium , potassium , urea , total bilirubin , glucose , creatinine , hemoglobin platelet count . ALT , AST , alkaline phosphatase , total WBC count value ( commonly elevate PKDL patient ) must grade 2 screening ( Appendix 3 ) . The following serology test must negative screening : HIV 1/2 ( patient &gt; 14 year age ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . All patient ( parent ) receive HIVrelated counsel prior testing . Patients positive HIV test result receive counsel University refer national AIDS control program treatment appropriate . Normal ECG . Potential study patient ( guardian ) must give write informed consent , willing admit hospital minimum 40 day 60 day , able attend require followup visit , permanent address , reachable study site personnel . Presence skin condition . Antileishmanial treatment within past 30 day . History previous exposure Leishmania vaccine . Known use injected oral corticosteroid within 6 week prior first administration study injection . Participation another experimental protocol receipt investigational product within 30 day prior first administration study injection . History autoimmune disease cause immunosuppressive state . History evidence acute chronic illness , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . ( Patients present concomitant illness refer standard clinical care ) . History use medication , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . History significant psychiatric illness . Known current drug alcohol abuser . Patients history previous anaphylaxis , severe allergic reaction vaccine unknown allergen , allergic reaction egg . Patients unlikely cooperate requirement study protocol . Known allergy contraindication SSG . Regardless eligibility , standard clinical care provide ( cost patient ) PKDL patient screen participation study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>PKDL</keyword>
</DOC>